

REMARKS

Claims 21-24 are currently active.

Applicant wishes to thank the Examiner for the detailed analysis identified in the Office Action.

The Examiner has rejected Claims 21-24 under 35 U.S.C. 101. Any reference to alphafetoprotein protein receptor binding sites in the claims has been deleted. There is now identified only one antigen.

The Examiner has rejected Claims 21-24 under 35 U.S.C. 112. Claim 21 has been amended to delete the language "in relation to normal non-malignant individuals". It is believed that this amendment obviates this rejection.

In view of the foregoing amendments and remarks, it is respectfully requested that the outstanding rejections and objections to this application be reconsidered and withdrawn, and Claims 21-24, now in this application be allowed.

Respectfully submitted,

RICARDO J. MORO

By Ansel M. Schwartz

Ansel M. Schwartz, Esquire

Reg. No. 30,587

One Sterling Plaza

201 N. Craig Street

Suite 304

Pittsburgh, PA 15213

(412) 621-9222

Attorney for Applicant

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 1/2/07

Ansel M. Schwartz
Ansel M. Schwartz
Registration No. 30,587